Home > Treatment Options > Tumor Suppressors > Clinical Trials >

AR 12

Last Updated: 03/28/17

Status: Determined Ineffective for NF2

Index

  • Treatment Information
  • Additional Information

Arno Therapeutics', AR12 and AR42 were treatment consideration for NF2. Following Phase 0 mice trials, AR42 was determined to be more likely to be effective. AR12 did not go further in clinical trials.

Treatment Information

Other Names
AR12, OSU-HDAR12, HDAR42
Pharmaceutical Company Arno Therapeutics
Prescription Information Arno Therapeutics - Drug Description
Expectation Change in Meningioma and Schwannoma in CNS

Inhibitor HDAC - Histone deacetylase inhibitors (HDACi), pan-HDAC inhibitor